SPR analysis was performed to explore the binding ability between IGF2BP3 and small molecule compounds that have therapeutic effects on RA, including celastrol, triptolide, medicarpin, curcumin, curbitacin B, and epigallocatechin (Figure S1A–E). The gene discussed is IGF2BP3; the disease is rheumatoid arthritis.